All In MedTech

Device Trial Radar · NCT02209610

Premature Fatigue in Veterans With Heart Failure: Neuronal Influences

Last checked: Nov 19, 2026Latest source record: Aug 2, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

32

Actual

Start

Jul 1, 2015

Primary completion

Jan 15, 2017

Study completion Jan 15, 2017

Sponsor

Lead sponsor
VA Office of Research and DevelopmentFederal agency
Sponsor type
Federal agency
Collaborators
University of Utah
First posted
Aug 6, 2014

More device trials from this sponsor

Design

Study type
Interventional
Phase
Early phase 1
Allocation
Randomized
Model
Parallel
Masking
Single (participant)
Primary purpose
Basic science
FDA-regulated device
No
Who can join
All sexes, from 20 years, up to 75 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

A hallmark of patients with heart failure (HF) is premature fatigue which impairs their quality of life and depicts a major source of morbidity. Premature fatigue may be attributed to a) contraction-induced transient changes within muscles (i.e. peripheral fatigue) and/or b) failure of the central nervous system to 'drive' / activate locomotor muscles (i.e. central fatigue). Both determinants of fatigue can lead to a reduction in a muscle's force and power generating capacity and to a compromised ability to perform whole body activities (e.g. walking). Recent findings in health have documented that group III/IV afferent fibers from the working muscle play a critical role in the development of both components of fatigue. Specifically, group III/IV muscle afferents limit central motor drive (CMD) during exercise and thereby exaggerate the development of central fatigue. In contrast, muscle afferents optimize muscle O2 delivery through the precise regulation of circulation and ventilation during exercise and thereby attenuate the development of peripheral fatigue.

Conditions

  • Heart Failure

Interventions

  • Electrical and Magnetic Nerve StimulatorsDevice

    Stimulation of motor nerve and central nervous system

  • Intrathecal FentanylDrug

    Mu-opioid receptor agonist

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Maximal Voluntary Quadriceps Force [% Change From Baseline]Time frame: 1 minute after exercise on study day
  2. Quadriceps Twitch Force and Voluntary Activation (% Change From Baseline)Time frame: During (20 second intervals) and 1 minute after exercise on study day
  3. Muscle Afferent AffectTime frame: 1 minute after exercise on study day

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • VA Salt Lake City Health Care System, Salt Lake City, UT

    Salt Lake City, Utah

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.